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Candida tropicalis has emerged as an important pathogenic fungus in nosocomial
infections due to its recalcitrant resistance to conventional antifungal agents, especially
to fluconazole (FLC). Berberine (BBR) is a bioactive herbal-originated alkaloids and has
been reported to possess antifungal functions against C. albicans. In this paper, we tried
to figure out the antifungal mechanisms of BBR and/or FLC in a clinical C. tropicalis
isolate 2006. In the microdilution test, the minimum inhibitory concentration (MIC) of
BBR was found 16 µg/mL with fractional inhibitory concentration index (FICI) 0.13 in
C. tropicalis 2006. The synergism of BBR and FLC was also confirmed microscopically.
After the treatments of BBR and/or FLC, the studies revealed that (i) FLC facilitated
BBR to increase reactive oxygen species (ROS), (ii) FLC enhanced the intranuclear
accumulation of BBR, (iii) BBR decreased the extracellular rhodamine 123 (Rh123)
via inhibiting efflux transporters, (iv) FLC assisted BBR to reduce ergosterol content,
and (v) BBR in combined with FLC largely downregulated the expressions of Candida
drug resistance 1 (CDR1) and CDR2 but impact slightly multidrug resistance 1 (MDR1),
and upregulate the expression of ergosterol 11 (ERG11). These results suggested that
BBR could become a potent antifungal drug to strengthen FLC efficacy in FLC-resistant
C. tropicalis via ROS increase, intracellular BBR accumulation, ergosterol decrease and
efflux inhibition.
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INTRODUCTION
The increased incidence of invasive fungal infection caused by Candida species (accounting
for approximately 80%) is of the main responsibility for high morbidity and mortality in
hospitalized patients (Weinstein et al., 2001; Snydman, 2003; Lass-Flörl, 2009). Although Candida
albicans remains the most common pathogenic fungi encountered, the frequency of isolation
of non-Candida albicans Candida (NCAC) species, i.e., C. tropicalis, C. krusei, C. glabrata and
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C. parapsilosis, has increased. In recent decades, C. tropicalis
has emerged as the first or second NACA species in patients
with cancer, neutropenia, malignancy and long-term medication,
and was frequently isolated from bloodstream (candidemia) and
urinary tract (candiduria) infections (Negri et al., 2012; Jiang
et al., 2013). C. tropicalis does not only have high proportions in
India, Brazil, and Taiwan, but is also becoming a critical public
health problem in China (Colombo et al., 2007; Ruan and Hsueh,
2009; Jiang et al., 2013).
The rising C. tropicalis infections can be mainly attributed
to the resistance to the conventional antifungal agents, such as
azoles especially (Negri et al., 2012). Fluconazole (FLC), one
of the first-line antifungal agents, is the most common used
azoles for prophylaxis and therapy to combat candidemia in
clinical practice. The clarified target of FLC is the lanosterol
14-α demethylase, a key enzyme responsible for the synthesis
of ergosterol which is a pivotal component in candidal cell
membrane encoded by ERG11 (Zavrel and White, 2015).
Except the mutation and overexpression of ERG11, respiration
deficiency leading to decreased reactive oxygen species (ROS)
and upregulation of drug eﬄux pump mediated by Cdr1p,
Cdr2p belonging to ATP-binding cassette superfamily (APC
transporter) and Mdr1p, a member of major facilitator
superfamily (MFS) have also been recently documented to result
in antifungal resistance of C. tropicalis to FLC (Vandeputte
et al., 2005; da Silva et al., 2013, 2014; Forastiero et al.,
2013; Jiang et al., 2013). The ever-increasing threat to FLC
resistance calls for an urgent search for novel antifungal
agents which possess strong antifungal activities alone or/and
improve antimycotic potential of FLC in C. tropicalis clinical
isolates.
Berberine (BBR), a bioactive herbal-originated alkaloid, has
been traditionally used in the treatments of gastroenteritis,
diarrhea, cholera, liver disease, inflammations and cancers due
to its anti-diarrhoeal, anti-malarial, anti-secretory and anti-
inflammation as well as anti-cancer effects with relatively low
cytotoxicity in vivo and in vitro (Chung et al., 1999; Zeng
et al., 2003; Kuo et al., 2004; Mantena et al., 2006). Recent
studies have been also demonstrated the favorable antibacterial
and anti-candidal activities of BBR against Staphylococcus
epidermidis, Staphylococcus aureus, Escherichia coli, C. albicans,
C. krusei, C. glabrata, and C. parapsilosis alone and/or
in combination with FLC under planktonic and/or biofilm
conditions (Yu et al., 2005; Wang et al., 2009; Iwazaki
et al., 2010; Wei et al., 2011; Kong et al., 2012; Li et al.,
2013). However, the antifungal effect of BBR on FLC-resistant
C. tropicalis and the underlying mode of action remain largely
unknown.
In the present study, we investigated the susceptibility of
BBR alone and in concomitant use with FLC to a FLC-
resistant C. tropicalis isolate via broth microdilution method,
checkerboard assay and time-kill test. The morphology changes
were inspected by scanning electron microscope (Vishnubalaji
et al., 2016) and fluorescent microscope. The measurements
of reactive oxygen species (ROS) and intracellular BBR
accumulation were performed through DAPI and DHR-123
staining. The eﬄux capability and ergosterol content were
surveyed by Rh 123 assay and HPLC method. Additionally, the
critical genes related to eﬄux pump and ergosterol synthesis, i.e.,
CDR1, CDR2, MDR1 and ERG11, were analyzed by quantitative
reverse transcription polymerase chain reaction (qRT-PCR).
MATERIALS AND METHODS
Isolates and Cultivation
Candida tropicalis ATCC750 was procured from NanJing Bian
Zhen Biotechnology Co., LTD. (Jiangsu, China), and the clinical
C. tropicalis isolate 2006 used in this study was kindly provided
by Clinical laboratory of Anhui Provincial Hospital (Anhui,
China). C. parapsilosis ATCC 22019 as the quality control
was kindly provided by Prof. YuanYing Jiang from College
of Pharmacy, Second Military Medical University (Shanghai,
China). All isolates were stored in YPD medium (1% yeast
extract, 2% peptone, 2% dextrose) and 20% glycerol at −80◦C.
The isolates were subcultured on Sabouraud Dextrose Broth
(SDB) for 24 h at 37◦C, and then the cells were harvested by
7500 rpm centrifugation and washed twice by sterile phosphate-
buffered saline (PBS). The fungal cells were resuspended in
RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) and cell
density was calculated using a hemocytometer for use.
In vitro Antifungal Activity
Microdilution method was adopted to determine the minimal
inhibitory concentration (MIC) of berberine (Xiao Cao, Xi’an,
China, Figure 1) and FLC (National Institutes for Food and
Drug Control, Beijing, China). Briefly, the cell suspension
(100 µL, 2 × 103 CFU/mL) was added into 96-well polystyrene
microtiter. After 1-h adhesion phase at 37◦C, the non-adherent
cells were washed away by PBS. The concentrations of BBR
were serially twofold diluted in a range from 1 to 512 µg/mL,
and those of FLC were prepared ranging from 0.125 to
1024 µg/mL. After 24-h incubation at 37◦C, the MIC80 was
defined as the lowest concentration of the agent at which
there was 80% inhibition of visible growth compared with the
control at the wavelength of 630 nm by a spectrophotometer
(SpectraMax M2/M2e, Wang Lab Sunnyvale, Stanford, CA,
USA). Subsequently, the checkerboard technique was performed
to evaluate the synergism of BBR and FLC. Briefly, the fungal
cells were diluted to 2 × 103 CFU/mL in RPMI-1640 medium
FIGURE 1 | Molecular structure of berberine (BBR).
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and added into each well. Then the cells were exposed to various
concentrations of FLC (0.03125-32 µg/mL) in combination
with different concentrations of BBR (0.25–16 µg/mL). The
interaction between BBR and FLC was determined by calculating
the fractional inhibitory concentration index (FICI) as follows:
FICI = (MICBBR in combination/MICBBR alone) + (MICFLC in
combination/MICFLC alone), in which synergism was interpreted
as FICI ≤ 0.5, indifference was defined as 0.5 < FICI ≤ 4.0, and
antagonism was FICI> 4.0.
Time-Kill Assay
The exponentially growing C. tropicalis 2006 cells were harvested,
resuspended in fresh RPMI 1640 medium, and adjusted to
5 × 104 CFU/mL. The concentrations of BBR and FLC were
set at 2 and 8 µg/mL according to each MIC in combination,
respectively. The cells were grown at 37◦C with constant shaking.
At designated time points (0, 2, 4, 6, 8, 12, 24, and 48 h),
the cell broth was pipetted out, centrifugated and rinsed by
sterile PBS before they were counted on sabouraud dextrose agar
(Dimaras et al., 2012). The control was free of FLC and BBR.
Compared to the most active drug alone, an increase/decrease in
killing of ≥2log10CFU/mL for the combination was defined as
synergy/antagonism, while the killing effect for the combination
of within 2log10CFU/mL compared with either agent alone was
defined as indifference.
Scanning Electron Microscope
The fungal supernatant (=2 mL, 2 × 106 CFU/mL) containing
agents (2 µg/mL BBR, 8 µg/mL FLC, and 2 µg/mL BBR plus
8 µg/mL FLC) were loaded on 6-well plate containing sterile
coverslips and incubated for 24 h at 37◦C. The control had
medium with no drugs. After incubation, the coverslip was taken
out and rinsed by sterile PBS. The samples were initially fixed in
2.5% glutaraldehyde overnight at 4◦C, and post-fixed with 0.1%
osmium tetroxide for 1 h. Then, the samples were dehydrated
sequentially by 30, 50, 70, 90, 95, and 100% ethanol for each step
20 min. After critical point drying, the coverslips were sputter-
coated with gold in a vacuum evaporator for morphological
observation by SEM JSM-6700F (JEOL, Musashino-shi, Tokyo,
Japan).
Fluorescein Diacetate (FDA) Assay
The fungal broth was adjusted to 2× 106 CFU/mL and incubated
respectively with 2 µg/mL BBR, 8 µg/mL FLC, and 2 µg/mL BBR
plus 8 µg/mL FLC samples for 24 h at 37◦C. The control was free
of drugs. The stock solution of fluorescein diacetate (FDA, Sigma,
Shanghai, China) was dissolved by acetone to a concentration of
10 mg/mL and stored at −20◦C prior to use. A 1:50 working
solution of FDA was freshly diluted in sterile PBS before each
assay. Subsequently, 100µL working solution of FDA plus 100µL
fungal solution was added into each pre-rinsed well in a 96-well
microtiter plate. The plate was incubated in the dark at 37◦C
for 30 min on a rocking table. The fluorescence in the well were
recorded with a fluorescent microscope (Olympus IX81, Tokyo,
Japan) at the excitation wavelength of 494 nm and the emission
wavelength of 518 nm, respectively (Peeters et al., 2008).
Measurement of Intracellular Reactive
Oxygen Species
The endogenous ROS in C. tropicalis 2006 cells was measured
with the fluorescent dye dihydrorhodamine-123 (DHR-123,
Sigma–Aldrich, USA) as described previously (Hao et al., 2013).
Briefly, the cells (1 mL, 2 × 106 CFU/mL) were suspended in
RPMI-1640 medium and mixed with different concentrations of
BBR and/or FLC for 24 h at 37◦C. After incubation, the cells
were harvested via centrifugation at 7500 rpm for 5 min, washed
with sterile PBS, resuspended in sterile PBS (6 × 106 CFU/mL),
and stained with 5 µg/mL DHR-123 in the dark at 37◦C for 30-
min incubation. The results were recorded and analyzed by a
FACSCalibur flow cytometer (Becton-Dickinson, USA).
Intracellular BBR Accumulation Assay
Intracellular BBR concentration was detected according to a
previously described protocol with a few modifications (Li et al.,
2013). Briefly, the isolate broth (=1 mL, 2 × 106 CFU/mL)
containing BBR (=2, 4, and 8 µg/mL) was cultured at 30◦C for
0, 2, 4, 6, and 8 h. After 3000 g of centrifugation and twice
washings, the pellets were resuspended in 1 mL of PBS. Then,
100 ml of each sample was transferred into a flat-bottomed 96-
well microplate (Greiner, Germany). The fluorescence of BBR was
measured by a spectrophotometer (SpectraMax M2/M2e, Wang
Lab Sunnyvale, Stanford, CA, USA) at the wavelengths of 405 nm
excitation and 520 nm emission. The intracellular localization
of BBR was performed according to the method as described
previously (de la Fuente-Salcido et al., 2007). Briefly, after the
exposure of fungal cells (=1 mL, 2× 106 CFU/mL) to BBR and/or
FLC for 8 h, the pullet was harvested, washed, and treated with
1 µg/mL of 4′,6-diamidino-2-phenylindole (DAPI) at 30◦C for
10 min in the dark. Living cells were immobilized on 0.1% poly-L-
lysine-coated slides and observed with a fluorescent microscope
(Olympus IX81, Tokyo, Japan) at the wavelengths of 340 nm
excitation and 488 nm emission.
Efflux Assay by RH123
The Rh123 (Sigma–Aldrich, Shanghai, China) assay was
administered according to the previous procedures with minor
modifications (Jiang et al., 2013). The fungal cells (=5 × 107
CFU/mL) were collected and transferred to fresh RPMI 1640
for 4-h incubation at 35◦C. Then the cells were harvested,
washed and resuspended in sterile PBS buffer. BBR (= 2, 4,
and 8 µg/mL), glucose (5%) and Rh123 (10 µM) were added
to the cell suspension and incubated at 35◦C in a shaker. After
incubation for 0, 10, 20, 30, 40, 50, and 60 min, the samples were
centrifuged at 7500 rpm for 5 min to pool the supernatants, and
the fluorescence was measured by a spectrophotometer at the
wavelengths of 501 nm excitation and 529 nm emission.
HPLC Evaluation
At first, the sterol was extracted in accordance to the methods
described before with a few modifications (Arthington-Skaggs
et al., 1999). After the treatments of BBR (= 2µg/mL) and/or FLC
(= 8 µg/mL), the fungal cells were harvested by centrifugation
at 7500 rpm for 5 min and washed twice with sterile PBS. The
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TABLE 1 | Primers used for RT-PCR.
Genes Forward (5′-3′) Reverse (5′-3′)
ERG11 CTACTCCCAAAAAAAACCATA TAAACCTAATCCCAAGACATC
CDR1 TGGAAAGAGTTGGAGGGTATGTTA TCCCAAGGTTTCGCCATC
CDR2 GCTTAGATGCCGCCACTG AGCCCATTCTGATGAAATACTC
MDR1 TTGGCGTTAGAGGATTTACTTTGG GAATGAAAACTTCTGGGAAAACTGG
ACT1 GACCGAAGCTCCAATGAATC AATTGGGACAACGTGGGTAA
TABLE 2 | Susceptibilities of BBR and/or FLC to Candida tropicalis isolates.
Isolates MIC80 alone (µg/mL) MIC80 in combination (µg/mL) FICI Interpretation
BBRa FLCb BBR FLC
C. parapsilosis ATCC 22019 16 0.5 8 0.25 1 IND c
C. tropicalis ATCC 750 16 0.5 8 0.125 0.75 IND
C. tropicalis 2006 16 1024 2 8 0.13 SYNd
aBBR, berberine; bFLC, fluconazole; c IND, indifference. dSYN, synergism.
wet pellet was adjusted to 0.50 g, mixed with 2.5 mL of 15%
alcoholic sodium hydroxide solution (15 g NaOH and 10 mL
sterile distilled water, brought to 100 mL with 100% ethanol)
and 1 mL sterile PBS, and agitated rigorously for 1 min. After
incubation in a water bath at 90◦C for 2 h, the cell suspensions
were removed to cool at room temperature, and subsequently
added with 3 mL of petroleum ether (Sinoreagent, China),
followed by a vigorous vortex for 3 min. The organic phase was
then transferred to a clean glass tube to evaporate petroleum ether
in a water bath at 60◦C. The extracted sterols were redissolved
in 1 mL of methanol (Sinoreagent, China) prior to HPLC-UV
analysis. The ergosterol content was detected using a modified
HPLC (Agilent 1100LC, Shanghai, China) based on the method
established previously (Peacock and Goosey, 1989). In brief, after
the filtration (pore size 0.22 mm, Millipore, Shanghai, China), the
sample containing ergosterol was analyzed at 282 nm with C18
reverse-phase column (ZorBax Eclipse Plus, 5, 4.6, and 100 mm,
Agilent, USA). The mobile phase was a solution of methanol in
dichloromethane (= 0.025%, v/v) at a flow rate of 1 mL/min with
a race time of about 20 min.
qRT-PCR Analysis
One milliliter cells (= 2 × 106 CFU/mL) was transferred into a
sterilized 6-well polystyrene microtiter plate (Corning, NY, USA).
After incubation with BBR and/or FLC at 37◦C for 24 h, the cells
were harvested by 7500 rpm centrifugation for 5 min. The drug-
free well was set as control. Pellets were washed thrice with sterile
PBS, and total RNA was extracted by using MagExtractor-RNA
kit (ToyoBo, Tokyo, Japan). cDNA was obtained through reverse
transcription reaction using the ReverTra Ace qPCR RT Master
Mix with gDNA Remover Kit (ToyoBo, Tokyo, Japan). The
prepared cDNA was diluted 10× fold before use. All experiments
were performed on ice. Primers of ERG11 (ergosterol 11),
CDR1 (Candida drug resistance 1), CDR2, MDR1 (multidrug
resistance 1) and ACT1 (actin 1), (Table 1) were synthesized by
Sangon Biotech (Shanghai, China). Real time PCR reaction was
conducted with SYBR Green I. The reaction was run on ABI7000
fluorescent quantitative PCR system (Applied Biosystem, USA)
with thermal cycling as follows: initial step at 95◦C for 60 s,
followed by 40 cycles at 95◦C for 15 s, 55◦C for 15 s, 72◦C for
45 s. All data were normalized to housekeeping gene ACT1, the
internal reference gene. Relative fold changes of the gene were
calculated using the formula 2−11Ct (Xie et al., 2011).
Statistical Analysis
All experiments were performed in triplicate. The results were
reported as mean ± standard deviation, calculated by SPSS 17.0,
and analyzed using one-way ANOVA. The comparison among
groups adopted t-test. P < 0.05 was considered as statistically
significant.
FIGURE 2 | Time-kill curves for C. tropicalis 2006 treated with BBR,
FLC and BBR + FLC.
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RESULTS
In vitro Antifungal Activities
The antifungal activities of BBR and/or FLC were firstly assessed
by broth microdilution method and checkerboard technique
in C. parapsilosis ATCC22019, C. tropicalis ATCC 750 and
C. tropicalis 03. The MIC80 of BBR alone were of 16 µg/ml,
but reduced to 8 µg/ml in C. parapsilosis ATCC22019 and
C. tropicalis ATCC 750, and 4 µg/ml in C. tropicalis 2006 when
BBR was in combined use with FLC. Without BBR, the MIC80
of FLC were of 1024 µg/ml, and sharply decreased 128 fold to
8 µg/ml in C. tropicalis 2006 with the aid of BBR. Although
the combined effect of BBR and FLC seemed indifference to
C. parapsilosis ATCC22019 and C. tropicalis ATCC 750 (FICI= 1
and 0.75> 0.5), both agents had synergistic effect on C. tropicalis
2006 with FICI 0.13 (Table 2). Subsequently, the time-kill test
was used for further evaluating the synergism of BBR and FLC
in C. tropicalis 2006. It could be observed that the antifungal
activity of 8 µg/mL of FLC was inferior to that of 2 µg/mL of BBR
during the tested time span. The required MIC of FLC decreased
by the addition of BBR. At 48-h incubation, the two drugs could
make an increase of 2.32 log10CFU/mL in killing compared
FIGURE 3 | The morphology of C. tropicalis 2006 treated with BBR, FLC and BBR + FLC by SEM (up, bar: 20 µm) and fluorescence microscopy
(down, bar: 20 µm).
FIGURE 4 | Reactive oxygen species (ROS) analysis by flow cytometer after the exposures to BBR (Left) and BBR + FLC (Right) in C. tropicalis 2006.
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to 2 µg/mL of BBR alone (the most active agent, Figure 2),
indicating the synergism of 2 µg/ml of BBR and 8 µg/ml of FLC
against C. tropicalis 2006. We also employed SEM and fluorescent
microscope to survey the morphological changes of C. tropicalis
2006 after the exposures of BBR and/or FLC. Compared with the
control, the hyphal cells were almost eradicated and only yeast-
form cells remained when BBR and FLC were used concomitantly
(Figure 3).
Intracellular ROS Accumulation
The ROS-specific dye DHR-123 could be oxidized to the
fluorescent rhodamine 123 by the intracellular ROS that could be
detected by fluorescent microscope. As shown, the intracellular
ROS levels increased along with the BBR concentrations from 2
to 8 µg/ml. It could also be observed that the intracellular ROS
level grew after the exposure to 2 µg/ml BBR + 8 µg/ml FLC
more than those after the exposure to 2 µg/ml BBR or 8 µg/ml
FLC in C. tropicalis 2006 (Figure 4).
Intracellular BBR Accumulation
Compared with the control, the fluorescent intensities did
not changed with significant differences in the BBR-treated
FIGURE 5 | (A) The fluorescence intensities of BBR were measured by
spectrophotometer at the wavelengths of 405 nm excitation and 520 nm
emission in C. tropicalis 2006. The intracellular localization of BBR was
observed by fluorescent microscope at the wavelengths of 340 nm excitation
and 488 nm emission after the medications of (B) no drug (control), (C) FLC,
(D) BBR, and (E) BBR + FLC in C. tropicalis 2006. ∗p < 0.05, compared with
the control.
(= 2 µg/ml) or FLC-treated (= 8 µg/ml) cells, but rose
remarkably after 2 h of exposures to BBR and FLC in C. tropicalis
2006 (p < 0.05, Figure 5A). For further validation, we used
fluorescent microscope to examine the intracellular localization
of BBR which could emit yellow fluorescence (Li et al., 2013).
Compared with the control, the FLC-treated cells had no
fluorescence (Figures 5B,C), whereas there were BBR-emitted
yellow fluorescence in BBR-treated cells (Figure 5D). After
the exposure to BBR in combination with FLC, the visibly
yellow fluorescence became strong (Figure 5E). Notably, the
fluorescence emitted by BBR was particularly strong in the
nucleus and overlapped with the nucleus dye DAPI (Figure 5E),
suggesting that FLC could facilitate BBR to accumulate in
C. tropicalis nucleus.
Effect of BBR on RH123 Efflux
To clarify the relationship of intracellular BBR accumulation
with eﬄux pump, we chose Rh123, a substrate of multidrug
resistance (MDR) protein (Clark et al., 1996), to detect the
extracellular Rh123 concentration. As shown, the extracellular
Rh123 concentration increased along with the increasing BBR
concentrations from 2 to 8 µg/ml. Compared with the control,
the extracellular Rh123 concentrations rose significantly after
20 min of incubation with 8 µg/ml of BBR (p < 0.05) and
40 min of incubations with 2 and 4 µg/ml of BBR (p < 0.05,
Figure 6).
Ergosterol Analysis by HPLC
The standard ergosterol peaked at about 15.26 min in HPLC
(Figure 7). Compared with the control (Figure 7), the peak
area seemed unchanged in the treatment of 2 µg/ml BBR
FIGURE 6 | The extracellular concentrations of Rh123 were detected
by spectrophotometer at the wavelengths of 501 nm excitation and
529 nm emission after the co-incubations with BBR for 0, 10, 20, 30,
40, 50, and 60 min in C. tropicalis 2006. ∗p < 0.05, compared with the
control.
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FIGURE 7 | Ergosterol content surveyed by HPLC after the administrations of BBR, FLC, and BBR + FLC in C. tropicalis 2006.
FIGURE 8 | Gene expressions of CDR1, CDR2, MDR1 and ERG11 in
C. tropicalis 2006 under treatments. ∗p < 0.05, compared with the control.
(Figure 7), and declined by sevenfold when 8 µg/ml FLC was
used (Figure 7). After the combined use of 2 µg/ml BBR and
8 µg/ml FLC, the peak area reduced by approximately twofold
in comparison with that of 8 µg/ml FLC and 14-fold compared
with the control (Figure 7).
Gene Expressions by qRT-PCR
To further explain the possible involvements of eﬄux pump
and ergosterol synthesis in the antifungal activity of BBR and/or
FLC against FLC-resistant C. tropicalis 2006, the expressions
of CDR1, CDR2, MDR1 and ERG11 genes were assessed by
qRT-PCR. Compared with the control, it was observed that
the expression of (i) CDR1 increased 1.7-fold (p < 0.05), 9.9-
fold (p < 0.05) and decreased 3-fold (p < 0.05), (ii) CDR2
increased 1.1-fold and decreased 12.5-fold (p < 0.05), 10-fold
(p < 0.05), (iii) MDR1 increased 1.8-fold (p < 0.05) and 1.9-
fold (p < 0.05), and decreased 1.1-fold, and surprisingly, (iv)
ERG11 increased 4.6-fold (p < 0.05), 3.1-fold (p < 0.05) and
6.3-fold (p < 0.05) when the exposed concentrations of BBR,
FLC and BBR+FLC were of respectively 2, 8 and 2 + 8 µg/ml
(Figure 8).
DISCUSSION
With widely use of intrusive catheters and extensively abuse of
conventional antifungal agents, the fungal infections caused by
C. tropicalis have become a serious health problem worldwide.
The ever-increasing isolations of C. tropicalis resistant to FLC
contribute to therapeutic failures. Currently, there are at least two
common efforts for antifungal drugs to control the infections by
C. tropicalis. One is to find or synthesize novel classes of potent
antifungal agents with low toxicity, the other is to discover “old
drugs” which have not been used for antifungal purpose before
but can improve the antifungal activity of the conventional agents
(such as FLC). The advancement of the former effort is quite
slow, while the second effort becomes a promising alternative
in the treatment of C. tropicalis. Meanwhile, it is meaningful
to investigate the mechanism of action of the “old drugs”
which will be helpful for understanding drug resistance and
searching new drug targets (Vandeputte et al., 2005; Kothavade
et al., 2010; da Silva et al., 2013; Neto et al., 2014; Choi et al.,
2016).
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Berberine existent in a variety of medicinal plants has been
previously reported to possess broad-spectrum antimicrobial as
well as antifungal activities. The published reports revealed that
BBR seemed to be more potent against pathogenic fungi than
bacteria. In Candida species, C. tropicalis appeared to be more
susceptible to BBR than C. albicans (Wei et al., 2011). Several
reports have demonstrated the synergism of BBR with FLC
against C. albicans, but we did not find records on the antifungal
activity of BBR combined with FLC in C. tropicalis. In this study,
we demonstrated that BBR could improve the antifungal activity
of FLC in a FLC-resistant C. tropicalis isolate 2006. To further
define the synergism of the two drugs, however, we will employ
more clinical C. tropicalis isolates resistant to FLC in a next
experiment.
To clarify the antifungal mechanism of BBR in combination
with FLC in C. tropicalis 2006, their individual antifungal
mode of action should also acquire thoughtful considerations.
In a previous study, the combination of BBR and FLC was
reported to contribute to the augmentation of intracellular
ROS accumulation via enhancing the tricarboxylic acid cycle
and inhibiting the ATP-synthase activity in C. albicans (Xu
et al., 2009). Our results showed that the ROS level increased
alone with the rising of BBR, and BBR plus FLC could
promote the endogenous ROS level in C. tropicalis 2006.
Further experiments demonstrated that FLC could facilitate
intracellular BBR accumulation and Rh123 outflow by hindering
the normal function of Mdr1 which is an important eﬄux pump
transporter belonging to the major facilitator superfamily (MFS).
The accumulation of BBR promoted by FLC could enhance
the antifungal activity of BBR in turn once BBR reached an
effective intracellular concentration (Stermitz et al., 2000; Ball
et al., 2006; Samosorn et al., 2009; Ettefagh et al., 2011). In
addition, several lines of evidence indicated that BBR could
be a DNA intercalator with preference to AT-rich sequence
(Davidson et al., 1977; Iwazaki et al., 2010). Combined with
fluorescence-emitting feature, we presumed that BBR could
bind DNA and accumulate mainly in nucleus in C. tropicalis
2006.
Ergosterol is a major constitute of fungal plasma membrane
and responsible for the integrity of cell membrane. The target
of FLC is lanosterol 14α-demethylase which is pivotal in the
synthesis of ergosterol (Zavrel and White, 2015). The changes of
ergosterol content would deepen our understanding concerned
with the combined mechanism of BBR and FLC. In this work,
the ergosterol contents were remarkably reduced by FLC and
BBR + FLC, inferring that FLC could assist BBR to inhibit the
growth of C. tropicalis 2006 via interfering the integrity of cell
membrane. These results were likely due to the fact that BBR
could improve the permeability of cell membrane by inhibiting
sterol 24-methyl transferase in the pathways of ergosterol (Park
et al., 1999; Park et al., 2001; Kim et al., 2004). Interestingly,
we noticed that BBR alone had no evident impact on ergosterol
content. Accordingly, we assumed that the targets of BBR and
FLC were different in cell membrane.
To further evaluate the effects of BBR and/or FLC on genes
in charge of eﬄux transporter and ergosterol synthesis, the
expressions of CDR1, CDR2, MDR1 and ERG11 genes were
assessed by qRT-PCR. BBR or FLC alone was not fully effective
to suppress the expressions of the former three genes, although
our results indicated that BBR alone could accelerate the Rh123
outflow via inhibiting MDR1 protein. This inconsistency might
be due to the fact that Rh123 and FLC did not, or at least partly,
share a common MDR1-like transporter alike the situation in
C. albicans (Clark et al., 1996). The relative significance among
CDR1,CDR2,MDR1 and ERG11 have been well-documented and
were different from that in C. albicans. Compared with ERG11,
the eﬄux pump genes do not seem to play a crucial role in azole
resistance inC. tropicalis (Vandeputte et al., 2005; Forastiero et al.,
2013; Jiang et al., 2013). To our surprise, the expressions of CDR1
and CDR2 were sharply inhibited, while the expressions of ERG11
appeared to be upregulated in the cases of BBR + FLC in this
work. We hypothesized that on one hand the isolate used was
limited in this work, and on the other hand, the targets of BBR
and FLC might be controlled by ERG11 although their targets
were different as described above, and the pathogen had to ascend
the expression of ERG11 to compensate the losses caused by BBR
and FLC but with no new synthesis of ergosterol. However, it is
reasonable to take ERG11 mutations including base-pair deletion
and/or amino acid substitution into account in future studies.
In summary, we demonstrated here the synergism of BBR and
FLC against FLC-resistant C. tropicalis, which is likely associated
with intracellular BBR accumulation followed by endogenous
ROS increase. In addition, we obtained a significant inhibition of
ergosterol biosynthesis as well as a decrease of eﬄux transporter.
The results also suggest that BBR can be a potential candidate for
the treatment of resistant C. tropicalis.
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